#USA #Radnor #Algeness #AAT #Lanzhou Biotechnique

Advanced Aesthetic Technologies Launches Algeness® VL in China

Advanced Aesthetic Technologies, Inc. (AAT) recently celebrated a significant achievement, announcing that its partner in China has secured approval to market its innovative dermal filler, Algeness® VL. This notable event, which underscores AAT's commitment to expanding its influence in the aesthetic medicine sector, positions the company for a successful entry into a vast and competitive market.

Algeness® VL is a unique injectable filler composed of a 2.5% agarose gel, recognized for its ability to fill facial wrinkles and restore lost volume. This product stands out as the first agarose-based injection filler to receive official approval in China, marking a crucial milestone for AAT and its development partner, Lanzhou Biotechnique Development Co., Ltd. (LanDev). LanDev is affiliated with the China National Biotec Group Company Limited, under Sinopharm Group, emphasizing the strong support structure behind this new addition to the aesthetic marketplace.

The announcement was made on January 29, 2025, amid growing anticipation within the industry and AAT's leadership. Doug Abel, the President and CEO of AAT, expressed his enthusiasm about this venture, highlighting LanDev's status as an ideal partner due to its expertise in the aesthetic field and its substantial market presence.

The journey of Algeness® involved extensive research and development focused on creating a biocompatible filler that meets aesthetic standards. The filler has undergone rigorous clinical evaluations to ensure safety and efficacy, leading to its approval not only in China but with ongoing efforts to gain clearance from the U.S. FDA for subsequent marketing in the United States.

Dr. Omer Buhsem, a renowned plastic surgeon based in Istanbul and the medical director of Algeness®, has conducted preclinical studies on the product. He advocates for Algeness® as a remarkable tool in aesthetic medicine, attributing its unique rheological properties to its effectiveness and safety. Feedback from numerous practitioners, including Dr. Tatjana Pavicic from Munich, Germany, reinforces Algeness®'s superior performance, with many patients expressing high satisfaction following treatments.

The growth trajectory of AAT has been buoyed by a series of strategic milestones over the past two years, including their successful clinical trials in preparation for FDA submission in 2025, gaining CE marking under stringent Medical Device Regulations, and acquiring a majority stake in Ghimas, the original developer of Algeness®.

The impending launch of Algeness® VL in China represents a transformative step for AAT, further enhanced by prospective approvals in additional international markets. Such advancements establish a solid foundation for introducing Algeness® as a premier choice in medical aesthetics globally. AAT remains dedicated to continuing its investment in research and technological innovation to solidify its position in the competitive landscape of aesthetic treatments.

With its biodegradable and 100% natural composition, Algeness® differentiates itself from conventional fillers that often include synthetic additives. Currently, it is available in various concentrations designed for specific cosmetic enhancements, targeting areas such as the nasolabial folds and facial contouring. The recent regulatory achievement in China will enable AAT to capitalize on the increasing demand for natural and effective aesthetic solutions, thereby further shaping the future of aesthetic medicine.

For more information on Algeness® and its offerings, visit Algeness.com.